Mendus AB (publ)

Clinical Progress

• Mendus has initiated the clinical development of its lead product, vididencel, in chronic myeloid leukemia (CML). The company-sponsored Phase 1b VITAL-CML trial has commenced, with the first patient enrolled to evaluate vididencel in patients with a sub-optimal response to tyrosine kinase inhibitors (TKIs).
• The company entered into an agreement with…